Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating a new medicine called Sofetabart Mipitecan Sofe-M in a three-part clinical trial for people with certain types of ovarian, peritoneal, and fallopian tube cancers. The study focuses on patients with platinum-resistant cancer, whose disease worsened during or within six months after platinum chemotherapy, and those with platinum-sensitive cancer, whose disease remained controlled for at least six months after platinum treatment. The trial aims to determine if Sofe-M is more effective and to better understand its safety compared to standard treatments. Participants receive different treatments depending on their group. In Part A, patients with platinum-resistant disease receive Sofetabart Mipitecan or chemotherapy or Mirvetuximab Soravtansine, all given intravenously. In Parts B and C, patients with platinum-sensitive disease receive Sofetabart Mipitecan plus Bevacizumab or platinum-based chemotherapy plus Bevacizumab, also administered intravenously. The choice of chemotherapy is made by the investigator. Treatments are given in parallel groups. During the study, participants undergo regular assessments including imaging scans to monitor disease progression, safety evaluations, and quality of life questionnaires. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, symptom changes, and drug levels in the blood. Each participants time in the study varies based on their response to treatment, with follow-up continuing up to 70 months after randomization to track outcomes and safety.
Actively Recruiting
Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.
Actively Recruiting
Researchers are evaluating if a combination of atezolizumab and standard chemotherapy can improve treatment outcomes for patients with sensitive relapse Extensive-stage Small Cell Lung Cancer ES-SCLC who have progressed after first-line treatment with platinum-etoposide chemotherapy plus PD-L1 inhibitors like atezolizumab or durvalumab. This phase II trial is designed to find out if continuing PD-L1 inhibition along with rechallenge chemotherapy increases overall survival and to monitor medical problems participants may experience. Eligible patients receive induction treatment with atezolizumab 1200 mg given intravenously on day 1 every 3 weeks along with carboplatin and etoposide chemotherapy for up to 4 cycles. After induction, patients continue maintenance therapy with atezolizumab every 3 weeks for up to 18 cycles or one year. Treatment continues until disease progression, unacceptable side effects, patient choice, or loss of clinical benefit. The study spans an expected 45 months, including 24 months for recruitment, 15 months maximum treatment duration, and up to 6 months of follow-up. Participants visit the clinic every 3 weeks for treatment, checkups, and tests. Radiological assessments using CT scans are done at 6 weeks, 12 weeks, and then every 12 weeks to check treatment response. Researchers continuously monitor safety and adverse events during treatment. The primary outcome is overall survival over about one year, with additional measures including progression-free survival and the frequency of adverse events. Participants are closely observed throughout the study to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the clinical characteristics and procedural outcomes of patients receiving permanent cardiac pacing to treat various heart rhythm disorders. This observational study compares the effectiveness and safety of different device implantation methods used in routine clinical practice, including the contribution of advanced non-fluoroscopic anatomical and electrophysiological mapping systems. The study focuses on patients over 18 years old who require a pacemaker or intracardiac defibrillator implant following European Society of Cardiology guidelines. The study includes several types of cardiac pacing approaches conventional right ventricular pacing, conduction system pacing such as His bundle or left bundle branch area pacing, cardiac resynchronization therapy CRT with biventricular or left ventricular pacing, epicardial pacing often done during cardiac surgery, and leadless pacing via a percutaneous femoral vein approach. Each method involves implantation of a device connected to cardiac leads positioned in specific heart locations, with vascular access through veins like the cephalic, axillary, or subclavian. Electrical parameters such as pacing threshold and sensing are measured to ensure device stability before final placement. Participants will be followed for up to 120 months with clinical and procedural data collected, including assessments of device efficacy and safety at 30 days, 6 months, and 12 months. Outcome measures include stable electrical device performance, absence of cardiovascular hospitalizations or death, and monitoring for heart failure or arrhythmia events. The study also tracks procedural times, radiation exposure, and complications such as infections or lead dislocations. This long-term observation aims to understand the benefits and risks of various pacing strategies in real-world settings.
Actively Recruiting
Researchers are evaluating a treatment approach for patients with metastatic pulmonary large-cell neuroendocrine carcinoma LCNEC who have not received prior therapy. This prospective multicenter phase II study aims to assess the combination of durvalumab with carboplatin and etoposide chemotherapy as a first-line treatment in this population. Participants will receive an induction phase of intravenous durvalumab 1500 mg on day 1, carboplatin AUC 5 on day 1, and etoposide 100 mgsqm on days 1-3 every three weeks for up to 4 cycles or until disease progression, unacceptable side effects, or other stopping reasons. Following this, patients enter a maintenance phase receiving durvalumab 1500 mg intravenously every 4 weeks for up to 24 additional courses, totaling 28 courses or 2 years of treatment, whichever comes first. Throughout the study, participants will undergo regular clinical assessments to monitor treatment effects, side effects, and disease status. Researchers will measure treatment efficacy using established criteria over one year. Safety and tolerability will also be closely tracked. The total duration of participant involvement may last up to 2 years or until disease progression or intolerable toxicity occurs.
Actively Recruiting
Researchers are evaluating the addition of Atezolizumab to a chemotherapy regimen called FOLFOXIRI plus Bevacizumab as the first treatment for patients with metastatic colorectal cancer that has proficient mismatch repair pMMR and high Immunoscore IC. This phase III, open-label, randomized trial aims to compare how well this combination works in delaying cancer progression, known as Progression Free Survival PFS. Participants will be randomly assigned to one of two groups. One group receives FOLFOXIRI plus Bevacizumab treatment every two weeks for up to 8 cycles, followed by maintenance therapy with 5-FULV plus Bevacizumab until cancer progresses or side effects become unacceptable. The other group receives the same treatment plus Atezolizumab, with a similar schedule and maintenance phase including Atezolizumab. Treatments involve intravenous infusions of multiple drugs, and dosing times vary from 30 minutes to several hours depending on the drug and cycle number. During the study, participants will undergo regular assessments including tumor measurements, quality of life questionnaires, and monitoring for side effects. Researchers will track outcomes such as cancer response rates, toxicity, overall survival, and quality of life over periods up to 48 months. The study includes safety monitoring and follow-up until disease progression, unacceptable toxicity, or patient choice to stop treatment.
Actively Recruiting
Researchers are conducting the HEROS study, a multi-center observational and prospective study in Italy, to investigate the current diagnostic and treatment approaches for HER2-mutated advanced non-small cell lung cancer NSCLC. This study works with the ATLAS project, which collects data from over 59 centers on newly diagnosed advanced NSCLC patients, to understand how common HER2 mutations are and how they are managed in routine clinical practice. Patients enrolled in the ATLAS project from September 2024 to September 2025 will be included to study the prevalence of HER2 mutations. Approximately 100 patients with HER2 mutations will be closely observed for secondary and exploratory objectives. Additionally, a subset of 25 centers will collect blood and tissue samples from available tumor sites to perform biomarker analyses, further exploring the biological characteristics of these cancers. Participants will be followed for 12 months after enrollment to track clinical information and outcomes. Data will be gathered from medical records and biomarker samples when available. The main measure of interest is the prevalence of HER2 mutations over one year. This observational study does not involve any investigational treatments, and participants will continue their usual care while contributing data to help improve understanding of HER2-mutated NSCLC.
Actively Recruiting
Researchers are evaluating the management of acute and chronic osteomyelitis in patients with diabetic foot syndrome, focusing on infections localized in the forefoot. This prospective multicenter randomized trial compares the effectiveness and safety of a bioactive glass device S53P4 against standard surgical care practices. The goal is to assess healing rates and other outcomes related to bone infection treatment in specialized centers. Participants are randomly assigned to one of two groups. Group A receives surgical removal of the infected bone and soft tissue debridement, along with systemic antibiotics and optional bone substitutes except bioactive glasses. Group B undergoes similar debridement but preserves the bone cortex while replacing infected soft bone with the S53P4 bioactive glass according to its approved use. Both groups aim for primary wound closure and may have vacuum drainage placed postoperatively. Participants are followed closely after surgery with biweekly visits up to three months or until healing, and then at six and twelve months. Assessments include wound evaluation, x-rays, histopathology, laboratory tests, and quality of life and foot function questionnaires. Researchers monitor healing progression, complications such as reinfection, recurrence rates, and functional recovery. The primary outcome is the healing rate at six months, with additional measures including antibiotic duration, re-interventions, amputations, and surgery characteristics.
Actively Recruiting
Researchers are conducting a real-life, national, multicenter, prospective study to observe how well patients with glaucoma or ocular hypertension OHT stick to their eye drop treatment using the connected device CONNECTDROP4. The study aims to measure the average yearly adherence rate, understand each patients adherence pattern, and explore how these adherence profiles relate to clinical data. Participants will use the CONNECTDROP4 device clipped onto an EASYGRIP4 eye drop bottle along with a smartphone app daily. This setup helps track the use of intraocular pressure IOP lowering eye drops over a one-year period. The study does not involve any experimental treatments but focuses on monitoring medication adherence in typical care settings. During the study, participants adherence rates are continuously recorded from the start until 12 months later. Researchers will analyze this data alongside clinical information to assess patterns and associations. The study provides a detailed view of how patients manage their glaucoma or OHT therapy in everyday life, with no intervention beyond regular treatment and device use.
1-10 of 16
1